Showing results (2141-2150 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|April 12, 2000
Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinicR M HoffmanInvestigational New Drugs|November 11, 1999
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drugI R Judson, P J Beale, J M Trigo, et al.Investigational New Drugs|November 11, 1999
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II studyN Vey, H Kantarjian, M Beran, et al.Investigational New Drugs|November 11, 1999
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinomaS Mani, D Sciortino, B Samuels, et al.Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.Investigational New Drugs|November 25, 2017
Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosisXin Liu, Huijie Wang, Xianghua Wu, et al.Investigational New Drugs|November 28, 2017
Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing miceSaeede Enteshari, Jaleh Varshosaz, Mohsen Minayian, et al.Investigational New Drugs|March 1, 2018
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patientsTeresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.Investigational New Drugs|January 6, 2019
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II studyClinton Yam, Francisco J Esteva, Miral M Patel, et al.Investigational New Drugs|January 7, 2019
Significant differences on submission lag following regulation reform for registration of novel therapeutic drugs in TaiwanI-Chen SunPageof 372